Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous SLAMF7 CAR-T cells in relapsed or refractory multiple myeloma
2024-512643-23-00Phase 2Authorised
- Sponsor
- University Hospital Würzburg
- Start
- Jan 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of SLAMF7 CAR-T in multiple myeloma (MM) (5 arms), sponsored by University Hospital Würzburg. Planned start Jan 2025; status: authorised.
02
Drugs
SLAMF7 CAR-T
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-512643-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512643-23-00.